Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Inclusion Criteria:

• Adult participants ≥19 years of age
• Diagnosis of moderate-to-severe plaque psoriasis
• Candidate for phototherapy or systemic therapy
• Will begin deucravacitinib according to approved product label

Exclusion Criteria:

• Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
• Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)